Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Achillion Pharmaceuticals has started dosing in a randomized, double-blind, placebo-controlled Phase 1 clinical trial to assess ACH-2684 as a treatment for hepatitis C virus (HCV) infection.
Subscribe to our email newsletter
The Phase 1 study will evaluate the safety, tolerability, pharmacokinetic profile and antiviral activity of ACH-2684.
The trial aims to enroll around 78 healthy subjects and 40 HCV infected patients.
In preclinical studies, ACH-2684 showed pico-molar potency, prominent pharmacokinetic properties and safety profile at high drug exposures.
Achillion president and CEO Michael Kishbauch said they expect to shortly launch the 12-week segment of the Phase 2 trial of their lead ACH-1625 protease inhibitor, as well as a Phase 1 trial of ACH-2928 NS5A inhibitor.
"We believe we remain poised to deliver a trio of important HCV clinical milestones near the end of this year, namely, 12-week EVR results on ACH-1625 and human proof-of-concept data on both ACH-2684 and ACH-2928," Kishbauch said.